UXN유엑스엔

UXN is a small Konex-listed glucose monitoring developer whose shares have fallen sharply over the past year, with recent filings pointing to financing activity and a disclosure designation.

UXN develops enzyme-free continuous glucose monitoring devices under the AGMS brand, with a market value of about ₩31.4B at a ₩6,300 close on 2026-10-16. The shares are down 39.4% over one year, though up 2.4% over one month. The data provided contains no financial statements, earnings, or valuation multiples, so the company's current financial position cannot be assessed from this pack.

What stands out

• No annual or trailing financial results are included in the data, so revenue, profit and cash position are not known from this pack.
• Recent filings include a rights offering decision and an amended convertible bond issue decision, both from August 2026, plus a securities issuance results notice.
• A September 2026 notice designated UXN an unfaithful disclosure company over a reversal of disclosure, which is a regulatory matter named in the filings.
• Three patent-rights acquisition disclosures for continuous analyte measuring devices were filed between late September and early October 2026.
• The share price is ₩6,300 against a 52-week range of ₩4,870 to ₩11,980, and foreign and institutional net flows over 20 days were zero, with retail net buying of about ₩1.9B.

What to watch

• Whether the rights offering and convertible bond issue proceed, and how they affect the share count and dilution.
• Any follow-up on the unfaithful disclosure designation and whether the company resolves the disclosure issue.
• Future filed financial statements, since none are currently available in the data pack to show revenue or profitability.